SCHEMBL24205641

SCHEMBL24205641

COC(=O)c1cc(F)c(Br)cc1C(=O)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.43
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 4/20 0.36
DPP4 P27487 2/20 0.35
GAA P10253 2/20 0.35
HSD17B10 Q99714 2/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
ATM Q13315 1/20 0.35
CFTR P13569 2/20 0.35
NOTUM Q6P988 1/20 0.35
TP53 P04637 1/20 0.34
SIRT6 Q8N6T7 1/20 0.34
CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26732901 1.00 SOS1 (0.43) SOS1LMNATSHRNPSR1KDM4E
SCHEMBL31394743 0.88 SOS1 (0.51) SOS1LMNATSHRNPSR1KDM4E
SCHEMBL24801995 0.82 SOS1 (0.47) SOS1LMNATSHRNPSR1KDM4E
SCHEMBL23526138 0.82 SOS1 (0.47) SOS1LMNATSHRNPSR1KDM4E
SCHEMBL30451450 0.82 CA12 (0.39) TSHRKDM4EALDH1A1HSD17B10GLA
SCHEMBL26732899 0.82 CA12 (0.39) TSHRKDM4EALDH1A1HSD17B10GLA
SCHEMBL26732898 0.82 CA12 (0.39) TSHRKDM4EALDH1A1HSD17B10GLA
SCHEMBL1044961 0.80 SOS1 (0.46) SOS1LMNATSHRNPSR1KDM4E
SCHEMBL31079873 0.80 SOS1 (0.50) SOS1LMNATSHRNPSR1KDM4E
SCHEMBL365953 0.80 SOS1 (0.50) SOS1LMNATSHRNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 US disclosed
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 US disclosed
CN-116804004-A Compounds as DHODH inhibitors 南京征祥医药有限公司 2023-09-26 CN disclosed
US-20230271943-A1 COMPOUNDS AS DHODH INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2023-08-31 US disclosed
US-20230271943-A1 COMPOUNDS AS DHODH INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2023-08-31 US disclosed
CN-116457343-A Compounds as DHODH inhibitors 南京征祥医药有限公司 2023-07-18 CN disclosed
EP-4196125-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2023-06-21 EP disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 CN disclosed
WO-2022036204-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2022-02-17 WO disclosed
WO-2022012548-A1 COMPOUNDS AS DHODH INHIBITORS NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2022-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 SOS1 1541/4885LMNA 1886/4885TSHR 4284/4885
US-20230271943-A1 COMPOUNDS AS DHODH INHIBITORS DHODH, DLD, DHRS9 SOS1 2692/4885LMNA 3421/4885TSHR 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.